On February 4, 2026, an Atlanta jury delivered the first-ever bellwether verdict in the Paragard IUD multidistrict litigation — and it went to the defense. The jury rejected the plaintiff’s claims that Teva failed to adequately warn about the risks of the Paragard intrauterine device breaking during removal and that the device was defectively designed, finding for the defense on all counts. As of October 2026, there are 4,224 pending lawsuits in the Paragard MDL — representing 47% growth since January 2025 — filed against the company in federal court in Georgia under MDL 2974. For those thousands of women with active cases in the Northern District of Georgia, that February headline may feel devastating. But mass tort litigation rarely moves in a straight line, and one defense verdict in a carefully selected test case does not define what happens to thousands of remaining claims. Here is what the February 2026 result actually means — and why the April 2027 second bellwether trial may matter far more.
What Happened in the First Paragard IUD Bellwether Trial
Pauline Rickard’s Paragard IUD broke during removal, requiring a hysteroscopy procedure to retrieve device fragments left inside her body. Her attorneys argued that Teva Pharmaceuticals — the original manufacturer — and CooperSurgical, which acquired the device in 2017, failed to adequately warn patients and physicians about the known risk of IUD fracture during removal and that the device itself was defectively designed. After a two-week trial, the jury rejected claims that Teva failed to adequately warn about Paragard’s propensity to break or that the device was defectively designed.
The Paragard IUD is a copper, T-shaped intrauterine device. Unlike hormonal IUDs, it relies entirely on copper’s spermicidal properties. Thousands of women allege that the device’s arms fracture at removal, leaving fragments that migrate or embed in uterine tissue, sometimes requiring hysteroscopies, laparoscopies, or even hysterectomies to address. People with Paragard IUDs and their medical providers have made more than 54,000 reports to the Food and Drug Administration (FDA) since Paragard was FDA-approved in 1984, according to publicly available data in the FDA Adverse Event Reporting System (FAERS) database. Of the more than 54,000 reports, nearly 24,000 have involved serious health problems, as classified by the FDA. According to the FDA, there have also been 22 related deaths. Separately, according to the FDA’s Adverse Events Reporting System (FAERS), there were 9,618 reports of device breakage specifically from 2009 through October 29, 2025.
Following the verdict, U.S. District Judge Leigh Martin May signaled that she is considering adjustments to the MDL’s bellwether trial plan. The judge’s review reflects the impact of the first trial outcome on the planned sequence of representative trials. Additionally, a settlement mediator — retired Atlanta judge M. Gino Brogdon Sr. — has already been appointed and tasked with getting the two sides working toward a global settlement. Those two developments together tell a more nuanced story than a simple defense win.
Why a Defense Verdict Does Not Doom Remaining Paragard IUD Claims
Bellwether trials serve one primary purpose in mass tort litigation: they give both plaintiffs and defendants a realistic preview of how juries respond to the core legal and scientific arguments in a given MDL. They are test cases by design, not binding precedents. The defense verdict in Rickard v. CooperSurgical tells both sides how one jury responded to one plaintiff’s specific evidence, but it does not legally determine the outcome of the more than 4,200 remaining cases.
Plaintiffs’ attorneys handling Paragard IUD cases have noted that the first bellwether result, while disappointing, provides critical information about how to sharpen the presentation of evidence, expert testimony, and damages arguments in future trials. The surge in case filings — with the MDL growing 47% since January 2025 to reach 4,224 pending lawsuits as of October 2026 — suggests that the plaintiffs’ bar remains confident in the underlying legal theories. Defense verdicts in the first round of bellwether trials have preceded large global settlements in other major MDLs, including cases involving transvaginal mesh and metal-on-metal hip implants. A single jury’s decision in one case does not erase the litigation risk that defendants face when thousands of similar claims remain pending.
It is also worth noting that no Paragard IUD settlements or verdicts resulting in plaintiff compensation have been reached as of late 2026. That means the litigation is still in a formative phase. The defendants have not yet demonstrated they can consistently win at trial across a range of plaintiff profiles, and the plaintiffs have not yet shown they can secure plaintiff verdicts. That uncertainty cuts both ways and is precisely the environment in which global settlement negotiations tend to intensify.
Key MDL Data: Paragard IUD Cases at a Glance (2026)
Understanding the scale and trajectory of the Paragard IUD MDL helps contextualize what is at stake. The following data points reflect the litigation as of October 2026:
- 4,224 lawsuits currently pending in MDL 2974 in the Northern District of Georgia
- 47% growth in pending cases since January 2025
- 1 bellwether trial completed (defense verdict, February 4, 2026)
- 0 plaintiff verdicts or settlements reached to date
- April 12, 2027 — next scheduled bellwether trial (Robere v. Teva)
- 54,000+ adverse event reports filed with the FDA since 1984
- Nearly 24,000 of those reports classified as involving serious health problems
- 9,618 reports of device breakage recorded in FAERS from 2009 through October 2025
The continued growth in case volume is significant. Even after a defense verdict, new plaintiffs continue to file claims, which signals that attorneys evaluating these cases believe the litigation has viable pathways forward. Defendants, in turn, face the prospect of litigating thousands of individual cases to verdict if no global resolution is reached — a prospect that creates its own pressure toward settlement.
The Rescheduled Second Bellwether and What It Means for Settlement
The second federal bellwether trial, Robere v. Teva, was originally scheduled for September 2026 but has been pushed to April 12, 2027. The rescheduling is notable for several reasons. It extends the period of uncertainty for plaintiffs currently in the MDL, but it also gives both sides additional time to engage in the mediation process being overseen by retired judge M. Gino Brogdon Sr.
In mass tort litigation, the gap between bellwether trials is frequently when the most consequential settlement discussions occur. With the first trial resulting in a defense verdict and the second trial now set for spring 2027, the parties have a window of roughly six months in which the pressure of an imminent jury decision is not yet acute — but the lessons of the first trial are fresh. That combination can make productive negotiation more likely.
If Robere v. Teva proceeds as scheduled in April 2027 and results in a plaintiff verdict, the dynamic in the MDL would shift considerably. A plaintiff win — particularly one accompanied by substantial damages — would dramatically increase the defendants’ exposure and motivation to resolve the remaining cases globally. Conversely, a second defense verdict would give the defendants additional leverage, though it still would not eliminate the litigation risk posed by thousands of pending claims across a range of individual fact patterns.
For women currently in the MDL, the April 2027 trial date is the next major milestone to watch. What happens in that courtroom in Atlanta will shape the settlement landscape for the entire litigation.
What Women With Paragard IUD Injuries Should Know Right Now
If you experienced a Paragard IUD breaking during removal, or if you required additional procedures — such as a hysteroscopy, laparoscopy, or hysterectomy — to address complications from a fractured device, your legal position has not materially changed because of the February 2026 defense verdict. Here is what matters most as the litigation moves into late 2026 and toward the 2027 second bellwether:
Your individual facts still drive your case’s value. Bellwether verdicts provide guidance on how juries may respond to certain arguments, but your specific medical history, the severity of your injuries, your treatment records, and the impact on your fertility and daily life are what ultimately determine the strength and potential value of your individual claim.
The MDL continues to grow. The 47% increase in pending cases since January 2025 reflects the ongoing assessment by experienced mass tort attorneys that these claims remain legally viable. Attorneys do not file cases they believe have no merit — doing so would waste resources and damage their standing in the MDL.
No settlements have been reached yet. As of October 2026, no global or individual settlements have been announced in the Paragard MDL. That means no compensation has been distributed, but it also means that the negotiation process is still open and ongoing.
Statute of limitations issues are real. If you have not yet filed a claim and you suffered a Paragard IUD injury, time matters. Statutes of limitations vary by state and can be as short as two years from the date of injury or discovery of harm. Consulting with a mass tort attorney promptly is important to preserve your rights.
The mediation process is active. The appointment of a dedicated settlement mediator reflects a recognition by the court and both parties that global resolution is an appropriate goal. While no timeline for settlement has been announced, the infrastructure for negotiation is in place.
Frequently Asked Questions About the Paragard IUD MDL Verdict
Does the February 2026 defense verdict mean my Paragard IUD case has no value?
No. The defense verdict in the first Paragard bellwether trial is not legally binding on any other case in the MDL. Bellwether trials are designed to test arguments and jury reactions, not to determine the outcome of thousands of individual claims. Your case is evaluated on its own facts — your specific device failure, your medical records, your resulting injuries and procedures, and the impact on your life. Many mass tort MDLs that have reached large global settlements experienced defense verdicts in early bellwether trials. The February 2026 result is one data point, not a final judgment on the merits of the broader litigation.
What is a bellwether trial and why does it matter for mass torts?
A bellwether trial is a representative test case selected from a larger pool of similar lawsuits consolidated in a multidistrict litigation. The goal is to give both sides — and the court — a realistic sense of how juries respond to the core facts, legal theories, and scientific evidence at the heart of the MDL. Bellwether results inform settlement negotiations by establishing a rough sense of litigation risk. They do not create legal precedent that binds other plaintiffs’ cases. A defense verdict in a bellwether can prompt plaintiffs’ attorneys to refine their approach; a plaintiff verdict can accelerate pressure on defendants to settle. Either way, bellwether trials are tools for information gathering and negotiation leverage, not final determinations of mass tort liability.
When is the next Paragard IUD bellwether trial scheduled?
The second federal bellwether trial, Robere v. Teva, is currently scheduled for April 12, 2027. It was previously set for September 2026 before being rescheduled. This trial is the next major litigation milestone for the Paragard MDL and will be closely watched by plaintiffs, defendants, and legal observers. A plaintiff verdict in Robere would significantly alter the settlement dynamics in the MDL; a second defense verdict would give defendants additional leverage, though it would not resolve the litigation risk posed by the more than 4,200 remaining pending claims.
How does a global settlement work in a mass tort MDL like the Paragard IUD case?
In a mass tort MDL, a global settlement is a negotiated agreement in which the defendants agree to pay a total sum — or create a settlement fund — to resolve a large number of individual claims at once. The settlement is typically structured by plaintiffs’ leadership counsel and defendants, with individual claim values determined by a point system or grid that accounts for injury severity, age, treatment required, and other factors. Participation is generally voluntary, but in practice the vast majority of plaintiffs in a resolved MDL choose to participate. In the Paragard MDL, a retired Atlanta judge has been appointed as a settlement mediator, which is a standard mechanism for facilitating these negotiations. As of October 2026, no settlement has been announced.
What types of Paragard IUD injuries are most likely to qualify for compensation?
The Paragard IUD claims at the center of MDL 2974 generally involve documented device fracture or breakage during removal, typically evidenced by medical records, imaging, or pathology reports. Injuries that tend to carry the most weight in these cases include those requiring surgical intervention to remove device fragments — such as hysteroscopy or laparoscopy — as well as cases involving perforation of the uterus or cervix, embedment of device fragments in tissue, and, in the most serious cases, hysterectomy necessitated by Paragard-related complications. Women who experienced fertility impacts as a result of their injuries may also have particularly significant claims. The strength of any individual claim depends heavily on the quality and completeness of the medical documentation, so gathering thorough records from all treating providers is an important early step.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.